Evofem Biosciences Secures Exclusive SOLOSEC Distribution Agreement for Sub-Saharan Africa Market

Key Takeaways

• Evofem Biosciences secured exclusive distribution rights for SOLOSEC in Sub-Saharan Africa through new partnership agreement
• SOLOSEC is an FDA-approved single-dose oral treatment for bacterial vaginosis and trichomoniasis affecting millions of women globally
• The agreement expands market access for women’s health treatments in underserved regions where these infections are prevalent

---

Evofem Expands Global Reach with African Distribution Deal

Women’s health company Evofem Biosciences, Inc. (OTCID: EVFM) announced an exclusive distribution and commercialization agreement for SOLOSEC® (secnidazole) 2g oral granules across Sub-Saharan Africa. The San Diego-based company’s move represents a significant expansion into emerging markets for its FDA-approved women’s health treatment.

About SOLOSEC Treatment

SOLOSEC offers a convenient single-dose oral treatment option for two common women’s health conditions: bacterial vaginosis and trichomoniasis. The FDA-approved medication provides healthcare providers and patients with a simplified treatment regimen compared to traditional multi-day antibiotic courses.

Bacterial vaginosis affects approximately 21.2 million women aged 14-49 in the United States alone, while trichomoniasis impacts an estimated 2.6 million people annually. These conditions are particularly prevalent in regions with limited healthcare access, making SOLOSEC’s single-dose convenience especially valuable.

Market Impact and Implications

The Sub-Saharan Africa distribution agreement positions Evofem to address significant unmet medical needs in women’s healthcare across the region. Many areas lack consistent access to multi-dose treatments, making single-dose therapies particularly important for treatment compliance and outcomes.

For Evofem, the partnership represents geographic diversification of its revenue streams while maintaining focus on women’s health innovations. The company has been working to expand SOLOSEC’s global footprint following its initial FDA approval and U.S. market launch.

Commercial Strategy

The exclusive nature of the distribution agreement provides Evofem’s partner with market exclusivity across Sub-Saharan Africa, potentially creating a strong foundation for market penetration and brand establishment. This approach allows Evofem to leverage local market expertise while maintaining product oversight and quality standards.

The agreement aligns with broader pharmaceutical industry trends toward expanding access to essential medicines in emerging markets, particularly for conditions disproportionately affecting women’s health outcomes.

---

Frequently Asked Questions

What conditions does SOLOSEC treat?

SOLOSEC is FDA-approved to treat bacterial vaginosis and trichomoniasis, two common women’s health infections. It provides a convenient single-dose oral treatment option.

When will SOLOSEC be available in Sub-Saharan Africa?

Evofem has announced the exclusive distribution agreement, but specific launch timelines and regulatory approval processes for individual Sub-Saharan African countries have not been disclosed.

How does SOLOSEC compare to existing treatments?

SOLOSEC’s main advantage is its single-dose convenience compared to traditional multi-day antibiotic treatments for bacterial vaginosis and trichomoniasis, potentially improving patient compliance and treatment outcomes.